Omnicom Group Free cash flow decreased by 120.5% to -$614.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 24.7%, from -$816.30M to -$614.40M. Over 3 years (FY 2021 to FY 2024), Free cash flow shows an upward trend with a 7.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $154.70M | $514.60M | $1.08B | -$567.70M | -$214.70M | $466.20M | $1.16B | -$545.20M | -$279.40M | $381.30M | $1.79B | -$641.60M | -$180.90M | $537.40M | $1.88B | -$816.30M | $3.00B | -$614.40M |
| QoQ Change | — | +232.6% | +110.6% | -152.4% | +62.2% | +317.1% | +149.8% | -146.8% | +48.8% | +236.5% | +368.6% | -135.9% | +71.8% | +397.1% | +249.5% | -143.5% | +467.3% | -120.5% |
| YoY Change | — | — | — | — | -238.8% | -9.4% | +7.5% | +4.0% | -30.1% | -18.2% | +53.4% | -17.7% | +35.3% | +40.9% | +5.1% | -27.2% | +59.7% | +24.7% |